Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database

Mostrar todas las versiones(2)

Abstract: Introduction. We explored the potential clinical effects of angiotensin-II AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in patients from the Parkinson’s Progress Marker Initiative (PPMI) study database. Methods. We included 423 newly diagnosed PD patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Udovin, Lucas Daniel, Otero Losada, Matilde, Bordet, Sofía, Chevalier, Guenson, Quarracino, Cecilia, Capani, Francisco, Pérez Lloret, Santiago
Formato: Artículo
Lenguaje:Inglés
Publicado: Elsevier 2021
Materias:
ESTUDIO DE CASOS
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEURODEGENERATIVAS
NEUROPROTECCION
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/11625
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-11625
record_format dspace
spelling I33-R139-123456789-116252023-11-22T21:52:09Z Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database Udovin, Lucas Daniel Otero Losada, Matilde Bordet, Sofía Chevalier, Guenson Quarracino, Cecilia Capani, Francisco Pérez Lloret, Santiago ESTUDIO DE CASOS ENFERMEDAD DE PARKINSON ENFERMEDADES NEURODEGENERATIVAS NEUROPROTECCION Abstract: Introduction. We explored the potential clinical effects of angiotensin-II AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in patients from the Parkinson’s Progress Marker Initiative (PPMI) study database. Methods. We included 423 newly diagnosed PD patients, free from antiparkinsonian treatment, from the PPMI. We compared the proportion of patients starting on L-DOPA during the first year of follow-up, and the changes in MDS-UPDRS total score and sub-scores during the first five follow-up years for patients exposed or not to ARBs or ACEIs. Results. Treatment with ARBs did not affect the proportion of patients on L-DOPA during the first year (adjusted OR, 95% CI= 0.26, 0.03-2.18, N.S.) while reduced MDS-UPDRS total score (0.85, 0.76-0.95, p<0.01). Patients treated with ACEIs experienced no changes in either measure. Conclusions. These results show potential signals for a beneficial effect with ARBs. Further clinical trials are warranted. 2021-06-15T15:01:39Z 2021-06-15T15:01:39Z 2021 Artículo Udovin, L. D., et al. Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database [en línea]. Postprint del artículo publicado en: Parkinsonism Relat Disord . 2021, 86. doi:10.1016/j.parkreldis.2021.03.007. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11625 1353-8020 https://repositorio.uca.edu.ar/handle/123456789/11625 10.1016/j.parkreldis.2021.03.007 33823471 eng Acceso abierto. 12 meses de embargo http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Elsevier Postprint del artículo publicado en: Parkinsonism Relat Disord . 2021, 86
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic ESTUDIO DE CASOS
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEURODEGENERATIVAS
NEUROPROTECCION
spellingShingle ESTUDIO DE CASOS
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEURODEGENERATIVAS
NEUROPROTECCION
Udovin, Lucas Daniel
Otero Losada, Matilde
Bordet, Sofía
Chevalier, Guenson
Quarracino, Cecilia
Capani, Francisco
Pérez Lloret, Santiago
Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database
topic_facet ESTUDIO DE CASOS
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEURODEGENERATIVAS
NEUROPROTECCION
description Abstract: Introduction. We explored the potential clinical effects of angiotensin-II AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in patients from the Parkinson’s Progress Marker Initiative (PPMI) study database. Methods. We included 423 newly diagnosed PD patients, free from antiparkinsonian treatment, from the PPMI. We compared the proportion of patients starting on L-DOPA during the first year of follow-up, and the changes in MDS-UPDRS total score and sub-scores during the first five follow-up years for patients exposed or not to ARBs or ACEIs. Results. Treatment with ARBs did not affect the proportion of patients on L-DOPA during the first year (adjusted OR, 95% CI= 0.26, 0.03-2.18, N.S.) while reduced MDS-UPDRS total score (0.85, 0.76-0.95, p<0.01). Patients treated with ACEIs experienced no changes in either measure. Conclusions. These results show potential signals for a beneficial effect with ARBs. Further clinical trials are warranted.
format Artículo
author Udovin, Lucas Daniel
Otero Losada, Matilde
Bordet, Sofía
Chevalier, Guenson
Quarracino, Cecilia
Capani, Francisco
Pérez Lloret, Santiago
author_facet Udovin, Lucas Daniel
Otero Losada, Matilde
Bordet, Sofía
Chevalier, Guenson
Quarracino, Cecilia
Capani, Francisco
Pérez Lloret, Santiago
author_sort Udovin, Lucas Daniel
title Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database
title_short Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database
title_full Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database
title_fullStr Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database
title_full_unstemmed Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression : an exploratory study in the PPMI database
title_sort effects of angiotensin type 1 receptor antagonists on parkinson's disease progression : an exploratory study in the ppmi database
publisher Elsevier
publishDate 2021
url https://repositorio.uca.edu.ar/handle/123456789/11625
work_keys_str_mv AT udovinlucasdaniel effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
AT oterolosadamatilde effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
AT bordetsofia effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
AT chevalierguenson effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
AT quarracinocecilia effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
AT capanifrancisco effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
AT perezlloretsantiago effectsofangiotensintype1receptorantagonistsonparkinsonsdiseaseprogressionanexploratorystudyintheppmidatabase
_version_ 1807949104171450368

Ejemplares similares